SARS-CoV-2 Spike (1197-1206)
LIDLQELGKY-acid
Description
Application Data
Description
-
LIDLQELGKY is an epitope from the SARS-CoV-2 spike protein (1197-1206). It can be an epitope for anti-viral targeting.
Application Data
-
Data Sheet Data Sheet Material Safety Data Sheet (MSDS)Catalogue number crb1001804 Molecular Weight 1190.7 Sequence (one letter code) LIDLQELGKY-acid
Sequence (three letter code) H-Leu-Ile-Asp-Leu-Gln-Glu-Leu-Gly-Lys-Tyr-OH
Purity >95% Storage -20°C References Ahmed et al., (2020). Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses, 12(3): 254. DOI: 10.3390/v12030254.
Manufactured in: United Kingdom The SARS-CoV-2 spike protein is present on the outside of the virus particles and can bind to angiotensin-converting enzyme II (ACE2) present on the host cells. The C-terminal receptor binding domain (RBD) of the spike protein binds to the N-terminal peptidase M2 domain of ACE2. This receptor binding results in the internalisation of the virus-receptor complex and is, therefore the mechanism of entry of SARS-CoV-2 into host cells.
The spike protein residues LIDLQELGKY (1197-1206) have been identified as a T-cell epitope with a predicted HLA restriction. Immune targeting of confirmed epitopes may potentially offer protection against SARS-CoV-2 and help the development of vaccines for long-lasting immunity.